Login to Your Account

BioMarin Files Aryplase BLA;EU Filing To Follow This Year

By Aaron Lorenzo

Tuesday, November 30, 2004
BioMarin Pharmaceutical Inc. moved Aryplase (galsulfase) into the FDA's hands, filing for approval of the enzyme-replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), an inherited and life-threatening disease for which no drug therapies are available. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription